July 8, 2020 / 3:10 PM / a month ago

BRIEF-Bergenbio Announces Amendment To Accord Clinical Trial Protocol For Bemcentinib As Potential Treatment For Covid-19

July 8 (Reuters) - Bergenbio ASA:

* BERGENBIO ANNOUNCES AMENDMENT TO THE ACCORD CLINICAL TRIAL PROTOCOL FOR BEMCENTINIB AS POTENTIAL TREATMENT FOR COVID-19

* BERGENBIO-UNDER AMENDMENT PATIENTS TO POTENTIALLY RECEIVE BEMCENTINIB PLUS ONE OR BOTH OF 2APPROVED COVID-19 TREATMENTS: DEXAMETHASONE AND REMDESIVIR Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below